Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 3/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.39 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954833 | 0.81 | ROCK1 (0.53) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL10857945 | 0.80 | CYP2A6 (0.42) | ROCK1CYP2A6PIM1PIM2PFKFB3 | |
| SCHEMBL8295552 | 0.80 | ROCK1 (0.56) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL10431976 | 0.77 | CYP2A6 (0.47) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL545078 | 0.77 | CYP17A1 (0.40) | CMA1PFKFB4 | |
| SCHEMBL11952640 | 0.74 | ROCK1 (0.50) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL10091955 | 0.74 | MAPT (0.56) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL5096663 | 0.74 | ROCK1 (0.50) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL8303440 | 0.74 | ROCK1 (0.50) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL3258493 | 0.74 | KDM4E (0.61) | ROCK1CYP2A6NPSR1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2964230-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-1731505-B1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-14 | — | — | EP | disclosed |
| WO-2014138692-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138692-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1175398-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173212-A1 | CONTRACEPTIVE COMPOSITIONS CONTANING INDOLONE DERIVATIVES AND PROGESTATIONAL AGENTS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066167-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ROCK1 4536/4885CYP2A6 1825/4885NPSR1 2840/4885 |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | ROCK1 553/4885CYP2A6 3697/4885NPSR1 4264/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | ROCK1 4453/4885CYP2A6 2122/4885NPSR1 3282/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | ROCK1 593/4885CYP2A6 600/4885NPSR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.